Metabolic Effects of Duodenal Jejunal Bypass Liner for the Treatment of Adipose Patients With Type 2 Diabetes Mellitus
The DJBL represents a novel, reversible intervention for managing obesity and T2DM, addressing a significant unmet need in the market for patients who have not succeeded with traditional weight loss methods. Given the rising prevalence of obesity and diabetes globally, this device could capture a substantial share of the weight loss and diabetes management market. The competitive landscape includes traditional bariatric surgeries and pharmacological interventions, but DJBL's non-invasive nature may offer a distinct advantage. Diligence considerations should focus on long-term efficacy, safety data, and potential regulatory pathways for commercialization.
Indication: Type 2 Diabetes Mellitus
Modality: medical device
Target: Duodenal-jejunal bypass liner (DJBL) mimicking biliodigestive digestion to induce weight loss and improve metabolic parameters in patients with Type 2 Diabetes Mellitus (T2DM).
Sponsor: Ruhr University of Bochum
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Duodenal-jejunal bypass liner (DJBL) mimicking biliodigestive digestion to induce weight loss and improve metabolic parameters in patients with Type 2 Diabetes Mellitus (T2DM).
View original source fields
Condition raw: Type 2 Diabetes Mellitus, Obesity
Condition normalized: Type 2 Diabetes Mellitus, Obesity
Modality raw: medical device
Modality normalized: medical device
Target raw: Duodenal-jejunal bypass liner (DJBL) mimicking biliodigestive digestion to induce weight loss and improve metabolic parameters in patients with Type 2 Diabetes Mellitus (T2DM).
Target normalized: Duodenal-jejunal bypass liner (DJBL) mimicking biliodigestive digestion to induce weight loss and improve metabolic parameters in patients with Type 2 Diabetes Mellitus (T2DM).